Literature DB >> 8140051

Immunopotentiation and delivery systems for antigens for single-step immunization: recent trends and progress.

M Z Khan1, J P Opdebeeck, I G Tucker.   

Abstract

The use of adjuvants for immunopotentiation has been investigated since the 1920s and a number of comprehensive reviews and monographs have been published on this subject. A recent trend in immunopotentiation has been the use of delivery systems which allow for sustained or controlled release of antigens and which induce prolonged immunity following a single dose. This concept has been termed either single-step or single-shot immunization. The delivery system has been modulated to potentiate the immune response either by delivering the antigen (and perhaps an adjuvant or adjuvants) either over a prolonged period of time or in a predetermined sequence or by incorporating substances with immunoadjuvant properties (e.g., lecithin and certain biodegradable polymers) as carriers within the delivery system. This Review focuses on the progress made in the design of delivery systems for immunopotentiation. Particular emphasis is given to delivery systems designed to achieve single-step immunization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8140051     DOI: 10.1023/a:1018977107167

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  50 in total

1.  Biodegradable microspheres. III: some immunological properties of polyacryl starch microparticles.

Authors:  P Artursson; I L Mårtensson; I Sjöholm
Journal:  J Pharm Sci       Date:  1986-07       Impact factor: 3.534

2.  A single-step immunization by sustained antigen release.

Authors:  I Preis; R S Langer
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

Review 3.  Effect of adjuvants on orally administered antigens.

Authors:  R J Genco; R Linzer; R T Evans
Journal:  Ann N Y Acad Sci       Date:  1983-06-30       Impact factor: 5.691

4.  Immune response mediated by liposome-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation.

Authors:  P N Shek; B H Sabiston
Journal:  Immunology       Date:  1982-12       Impact factor: 7.397

5.  Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own.

Authors:  N van Rooijen; R van Nieuwmegen
Journal:  Immunol Commun       Date:  1980

6.  Antibody response to bacterial antigens covalently bound to biodegradable polymerized serum albumin beads.

Authors:  C Langhein; J F Newman
Journal:  J Appl Bacteriol       Date:  1987-11

7.  Significance of Freund's adjuvant/antigen injection granuloma in the maintenance of serum antibody response.

Authors:  A K Lascelles; G Eagleson; K J Beh; D L Watson
Journal:  Vet Immunol Immunopathol       Date:  1989-08       Impact factor: 2.046

8.  Prolonged release of insulin by cholesterol-matrix implant.

Authors:  P Y Wang
Journal:  Diabetes       Date:  1987-09       Impact factor: 9.461

9.  Biodegradable serum albumin polymers for the sustained release of virus antigens in vaccines. A preliminary report.

Authors:  J B Dewar; D A Hendry; J F Newman
Journal:  S Afr Med J       Date:  1984-04-07

10.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; T R Tice; R M Gilley
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more
  2 in total

1.  Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys.

Authors:  M Singh; O Singh; G P Talwar
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

2.  Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccine.

Authors:  I Øynebråten; T-O Løvås; K Thompson; B Bogen
Journal:  Scand J Immunol       Date:  2012-04       Impact factor: 3.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.